Concord Biotech Limited
Concord Biotech Limited is a mainboard IPO raising ₹1,551 Cr at ₹705 – ₹741 a share. It listed on 18 Aug 2023 and trades at ₹1,255 today, +69.4% against its issue price of ₹741. It was subscribed 25× in total.
24.9 times more demand than shares on offer
populated partly populated we hold nothing here — the tab says why
Source documents
What the issuer and the exchanges published. Everything else on this tab is read out of these.
The full prospectus — business, financials, risk factors and litigation.
Which institutions were allotted shares before bidding opened, and how many.
Where physical applications could be submitted.
The issuer's own "basis of issue price": the earnings multiples it is asking for, and the peer companies it chose to compare itself against.
The full prospectus — business, financials, risk factors and litigation.
Read-out of the prospectus
A severity-ranked risk register with every item cited to its page, plus litigation counts and rupee exposure and related-party dealings, are being built from the prospectus above. We read prospectuses for current and upcoming issues — historical issues will not gain these sections.